Medical News Today -- A study published Online First by The Lancet Oncology reports that lenalidomide plus low-dose dexamethasone is linked to better short-term overall survival. In addition, it is associated with lower toxicity than lenalidomide plus high-dose dexamethasone in patients with newly diagnosed myeloma. Therefore it is a possible treatment option for these patients. Currently, high-dose dexamethasone is a basis of therapy for multiple myeloma. The article is the work of Professor S Vincent Rajkumar, Mayo Clinic, Rochester, MN, USA, and colleagues on behalf of the Eastern Cooperative Oncology Group (ECOG), USA.
